STOCK TITAN
  1. Home
  2. Sec-filings
  3. JAZZ
  4. [Form 4] Jazz Pharmaceuticals plc Insider Trading Activity

Jazz Pharmaceuticals (NASDAQ: JAZZ) awards 1,605 restricted stock units to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.

Jazz Pharmaceuticals plc reported that director Ted W. Love received a grant of 1,605 restricted stock units, each representing a contingent right to receive one ordinary share at a cash price of $0.00 per share.

The award was granted under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to his continuous service and other conditions. Following this grant, Love directly holds 3,132 ordinary shares.

Positive

  • None.

Negative

  • None.
Insider LOVE TED W
Role Director
Type Security Shares Price Value
Grant/Award Ordinary Shares F1 1,605 $0.00 $0.00
Holdings After Transaction: Ordinary Shares — 3,132 shares (Direct)
Footnotes (1)
  1. F1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
Restricted stock units granted 1605.0000 shares Non-derivative equity award to director on 2026-08-05
Grant price per share 0.0000 Cash price per ordinary share for the RSU grant
Holdings after transaction 3132.0000 shares Total ordinary shares directly held by Ted W. Love after the grant
RSU vesting date July 23, 2027 Date when all 1,605 restricted stock units vest in full
restricted stock units financial
"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting."
continuous service financial
"Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What equity award did JAZZ director Ted W. Love receive on August 5, 2026?
Ted W. Love received a grant of 1,605 restricted stock units of Jazz Pharmaceuticals ordinary shares. Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting, with no cash price paid for the award.

How many Jazz Pharmaceuticals (JAZZ) shares does Ted W. Love hold after this grant?
After the August 5, 2026 grant, Ted W. Love directly holds 3,132 ordinary shares of Jazz Pharmaceuticals. This total includes the newly granted 1,605 restricted stock units, reported as non-derivative holdings on the Form 4 filing.

When do the 1,605 restricted stock units granted to JAZZ’s director vest?
The 1,605 restricted stock units will vest in full on July 23, 2027. Vesting is subject to Ted W. Love’s continuous service with Jazz Pharmaceuticals and certain additional conditions described in the equity award terms.

Under what plan were Ted W. Love’s JAZZ restricted stock units granted?
The restricted stock units were granted under Jazz Pharmaceuticals’ 2007 Amended and Restated Non-Employee Directors Stock Award Plan. This plan governs equity awards made to non-employee directors, including the 1,605 restricted stock units reported for Ted W. Love.

Was Ted W. Love’s August 2026 JAZZ equity grant made under a Rule 10b5-1 plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as an affirmative plan. The reported grant of 1,605 restricted stock units therefore is not disclosed as executed under a Rule 10b5-1 trading plan in this filing.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LOVE TED W
(Last)(First)(Middle)
5TH FL, WATERLOO EXCHANGE
WATERLOO RD
(Street)
DUBLIN 4
(City)(State)(Zip)
IRELAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares08/05/2026A(1)1,605A$0.03,132D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
By: /s/Paz Dizon, as attorney in fact For: Ted W. Love08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR